The overall mission of the Experimental Therapeutics Program (ET) is to reduce the cancer burden through preclinical and early clinical drug development, to determine optimal treatment approaches, combinations and sequences, and to identify prognostic, predictive and surrogate markers of efficacy and resistance for active agents. Theme 1 is focused on targeting known driver pathways of cancer. Significant accomplishments include trial using identification of mediators of drug resistance to EGFR pathway targeted drugs and application of findings in a clinical trial. Theme 2 is focused on targeting the tumor microenvironment. Significant accomplishments include combinations of immune modulatory or antiangiogenic drugs with pathway targeted inhibitors. Theme 3 is focused on developing novel drugs and biomarkers. Significant accomplishments include establishing an algorithm for repurposing of existing drugs for cancer indications and the generation of conditionally reprogrammed cells from patients'specimens for functional and drug sensitivity screening. Under new leadership, ET is now guided by Giuseppe Giaccone, MD, PhD, former Chief of the NCI Medical Oncology Branch and a leading expert in lung cancer and experimental therapeutics, and Anton Wellstein, MD, PhD, a pharmacologist whose translational research is focused on tumor stromal interactions and mechanisms of cancer progression to metastasis. ET has 26 members, including translational and clinical researchers, representing 11 departments at Georgetown University and one at MedStar Washington Hospital Center. The Program is supported by $3M in total peer reviewed direct funding ($1.SM in NCI funding) on total funding base of $6M. From 2009 to 2012, 19 investigator-initiated trials have accrued 380 patients. In this reporting period, ET members published 339 scholarly manuscripts;42% are intra- and/or interprogrammatic;the latter including publications with members of all three other LCCC Programs. About half of the publications (48%) involve external collaborations. ET members use all LCCC Shared Resources. The Program is organized by disease and modality groups to focus clinical research activities and prioritize clinical trials. The Cancer Center has added value to the Program by providing institutional support ($19M), recruiting leaders in the field that have enhanced ET's focus, breadth and depth (Giaccone, Atkins, Tan) and establishing the MedStar Georgetown Cancer Network to facilitate clinical research across MedStar institutions and better serve LCCC's catchment area

Public Health Relevance

Research focuses on cancers prevalent in LCCC's catchment area. The Program's commitment to increasing accrual to clinical trials, particularly among Black patients who are most affected in the catchment area, is essential. Furthermore, the expansion of ET trials to other institutions in the MedStar Georgetown Cancer Network is enhancing the availability of cutting-edge clinical research to patients in the catchment area.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Georgetown University
United States
Zip Code
Lai, Chih-Hsin; Lai, Ying-Jung J; Chou, Feng-Pai et al. (2016) Matriptase Complexes and Prostasin Complexes with HAI-1 and HAI-2 in Human Milk: Significant Proteolysis in Lactation. PLoS One 11:e0152904
AlHossiny, Midrar; Luo, Linlin; Frazier, William R et al. (2016) Ly6E/K Signaling to TGFβ Promotes Breast Cancer Progression, Immune Escape, and Drug Resistance. Cancer Res 76:3376-86
Chung, Arlene E; Jensen, Roxanne E; Basch, Ethan M (2016) Leveraging Emerging Technologies and the ""Internet of Things"" to Improve the Quality of Cancer Care. J Oncol Pract 12:863-866
Brown, Lindsay; Gutherz, Samuel; Kulick, Catherine et al. (2016) Profile of retigabine-induced neuronal apoptosis in the developing rat brain. Epilepsia 57:660-70
Hunegnaw, Ruth; Vassylyeva, Marina; Dubrovsky, Larisa et al. (2016) Interaction Between HIV-1 Nef and Calnexin: From Modeling to Small Molecule Inhibitors Reversing HIV-Induced Lipid Accumulation. Arterioscler Thromb Vasc Biol 36:1758-71
Taylor, Kathryn L; Hoffman, Richard M; Davis, Kimberly M et al. (2016) Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer. Cancer Epidemiol Biomarkers Prev 25:1240-50
Allen, Megan; Ghosh, Suhasini; Ahern, Gerard P et al. (2016) Protease induced plasticity: matrix metalloproteinase-1 promotes neurostructural changes through activation of protease activated receptor 1. Sci Rep 6:35497
Boca, Simina M; Nishida, Maki; Harris, Michael et al. (2016) Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study. PLoS One 11:e0153461
Spikol, Emma D; Laverriere, Caroline E; Robnett, Maya et al. (2016) Zebrafish Models of Prader-Willi Syndrome: Fast Track to Pharmacotherapeutics. Diseases 4:
Cheema, Amrita K; Maier, Irene; Dowdy, Tyrone et al. (2016) Chemopreventive Metabolites Are Correlated with a Change in Intestinal Microbiota Measured in A-T Mice and Decreased Carcinogenesis. PLoS One 11:e0151190

Showing the most recent 10 out of 883 publications